Literature DB >> 6864885

Nosocomial urinary tract infections: secular trends, treatment and economics in a university hospital.

J N Krieger, D L Kaiser, R P Wenzel.   

Abstract

During a 71-month interval 3,024 nosocomial urinary tract infections were identified by prospective surveillance at our hospital. The annual attack rate varied between 2.0 and 3.1 per 100 admissions. Gram-negative bacilli caused 74 per cent of all urinary infections and recurrent infections in the hospital accounted for only 1 per cent. The most frequent pathogens were Escherichia coli (24 per cent), Pseudomonas aeruginosa (8 per cent), Streptococcus faecalis (7 per cent), Klebsiella pneumoniae (6 per cent) and Proteus mirabilis (6 per cent). Candida species caused 10 per cent of the infections and may represent a hospital-acquired pathogen of increasing importance. The burn unit had a significantly higher proportion of Enterobacter infections (21 per cent) than any other service (p less than 0.05). The plastic surgery service had more Serratia infections (24 per cent), whereas obstetrics and gynecology had more Escherichia coli infections (47 per cent) relative to other hospital services. More than 99 per cent of the patients with nosocomial urinary tract infections received antimicrobial drugs; in 63 per cent the chart documented that drug therapy was prescribed specifically for treatment of the urinary infections. Hospital-acquired urinary infections added approximately 1 million dollars to hospital expenses during the study interval. Estimates were made of the economic benefits of successful control programs.

Entities:  

Mesh:

Year:  1983        PMID: 6864885     DOI: 10.1016/s0022-5347(17)50980-5

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

1.  Comparison of asymptomatic bacteriuria Escherichia coli isolates from healthy individuals versus those from hospital patients shows that long-term bladder colonization selects for attenuated virulence phenotypes.

Authors:  Ellaine Salvador; Florian Wagenlehner; Christian-Daniel Köhler; Alexander Mellmann; Jörg Hacker; Catharina Svanborg; Ulrich Dobrindt
Journal:  Infect Immun       Date:  2011-11-21       Impact factor: 3.441

2.  Changing trends in frequency and antimicrobial resistance of urinary pathogens in outpatient clinics and a hospital in Southern Israel, 1991-1995.

Authors:  G Weber; K Riesenberg; F Schlaeffer; N Peled; A Borer; P Yagupsky
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-11       Impact factor: 3.267

3.  Ureteral blockage by Candida in a patient with urinary derivation type Camey.

Authors:  R G Aguilera; R R Aldosa; G Rius-Espina; J P López
Journal:  Int Urol Nephrol       Date:  1989       Impact factor: 2.370

4.  Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study.

Authors:  G D Fang; C Brennen; M Wagener; D Swanson; M Hilf; L Zadecky; J DeVine; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

5.  Randomized, double-blind comparison of ceftazidime and moxalactam in complicated urinary tract infections.

Authors:  E A Horowitz; L C Preheim; T J Safranek; M P Pugsley; C C Sanders; M J Bittner
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.